The Human Phospholipase B-II Precursor (HPLBII-P) in Urine as a Novel Biomarker of Increased Glomerular Production or Permeability in Diabetes Mellitus?
Abstract
:1. Introduction
2. Materials and Methods
3. Statistics
4. Results
5. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Xu, S.; Zhao, L.; Larsson, A.; Venge, P. The identification of a phospholipase B precursor in human neutrophils. FEBS J. 2009, 276, 175–186. [Google Scholar] [CrossRef]
- Xu, S.; Cai, L.; Zhao, L.; Douhan-Håkansson, L.; Kristjánsson, G.; Pauksen, K.; Venge, P. Tissue localization and the establishment of a sensitive immunoassay of the newly discovered human phospholipase B-precursor (PLB-P). J. Immunol. Methods 2010, 353, 71–77. [Google Scholar] [CrossRef]
- Castro Tejera, V.; Öhman, L.; Aabakken, L.; Fellström, B.; Hausken, T.; Hovde, Ø.; Hreinsson, J.P.; Lindberg, G.; Venge, P.; Simrén, M.; et al. Randomised clinical trial and meta-analysis: Mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity. Aliment. Pharmacol. Ther. 2022, 56, 968–979. [Google Scholar] [CrossRef] [PubMed]
- Lithell, H.; Sundström, J.; Ärnlöv, J.; Björklund, K.; Hänni, A.; Hedman, A.; Zethelius, B.; Byberg, L.; Kilander, L.; Reneland, R. Epidemiological and clinical studies on insulin resistance and diabetes. Upsala J. Med. Sci. 2000, 105, 135–150. [Google Scholar] [CrossRef] [PubMed]
- Lind, L.; Fors, N.; Hall, J.; Marttala, K.; Stenborg, A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 2368–2375. [Google Scholar] [CrossRef] [PubMed]
- Pavkov, M.E.; Collins, A.J.; Coresh, J.; Nelson, R.G. Kidney Disease in Diabetes. In Diabetes in America, 3rd ed.; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2018; Chapter 22. [Google Scholar]
- Kapoula, G.V.; Kontou, P.I.; Bagos, P.G. Diagnostic Accuracy of Neutrophil Gelatinase-Associated Lipocalin for Predicting Early Diabetic Nephropathy in Patients with Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. J. Appl. Lab. Med. 2019, 4, 78–94. [Google Scholar] [CrossRef]
- Żyłka, A.; Dumnicka, P.; Kuśnierz-Cabala, B.; Gala-Błądzińska, A.; Ceranowicz, P.; Kucharz, J.; Ząbek-Adamska, A.; Maziarz, B.; Drożdż, R.; Kuźniewski, M. Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients. Mediat. Inflamm. 2018, 2018, 7659243. [Google Scholar] [CrossRef] [PubMed]
- O’Sullivan, E.D.; Hughes, J.; Ferenbach, D.A. Renal Aging: Causes and Consequences. J. Am. Soc. Nephrol. 2017, 28, 407–420. [Google Scholar] [CrossRef]
- Mohandes, S.; Doke, T.; Hu, H.; Mukhi, D.; Dhillon, P.; Susztak, K. Molecular pathways that drive diabetic kidney disease. J. Clin. Investig. 2023, 133, 1–12. [Google Scholar] [CrossRef]
- Sato, Y.; Wharram, B.L.; Lee, S.K.; Wickman, L.; Goyal, M.; Venkatareddy, M.; Chang, J.W.; Wiggins, J.E.; Lienczewski, C.; Kretzler, M.; et al. Urine podocyte mRNAs mark progression of renal disease. J. Am. Soc. Nephrol. 2009, 20, 1041–1052. [Google Scholar] [CrossRef]
- Jana, S.; Mitra, P.; Roy, S. Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review. Diseases 2022, 11, 8. [Google Scholar] [CrossRef]
- Kondapi, K.; Kumar, N.L.; Moorthy, S.; Silambanan, S. A Study of Association of Urinary Nephrin with Albuminuria in Patients with Diabetic Nephropathy. Indian J. Nephrol. 2021, 31, 142–148. [Google Scholar] [CrossRef] [PubMed]
- Surya, M.; Rajappa, M.; Vadivelan, M. Utility of Urinary Nephrin in Patients With and Without Diabetic Nephropathy and Its Correlation With Albuminuria. Cureus 2021, 13, e20102. [Google Scholar] [CrossRef]
- Veluri, G.; Mannangatti, M. Urinary Nephrin is a Sensitive Marker to Predict Early Onset of Nephropathy in Type 2 Diabetes Mellitus. J. Lab. Physicians 2022, 14, 497–504. [Google Scholar] [CrossRef] [PubMed]
- Rangaswamaiah, H.; Somashekar, P.; Gutlur Nagarajaiah, S.R.; Ganesh, V. Urinary nephrin linked nephropathy in type-2 diabetes mellitus. Bioinformation 2022, 18, 1131–1135. [Google Scholar] [CrossRef]
- Valdivielso, J.M.; Jacobs-Cachá, C.; Soler, M.J. Sex hormones and their influence on chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2019, 28, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Ricardo, A.C.; Yang, W.; Sha, D.; Appel, L.J.; Chen, J.; Krousel-Wood, M.; Manoharan, A.; Steigerwalt, S.; Wright, J.; Rahman, M.; et al. Sex-Related Disparities in CKD Progression. J. Am. Soc. Nephrol. 2019, 30, 137–146. [Google Scholar] [CrossRef]
- Jobs, E.; Risérus, U.; Ingelsson, E.; Sundström, J.; Jobs, M.; Nerpin, E.; Iggman, D.; Basu, S.; Larsson, A.; Lind, L.; et al. Serum cathepsin S is associated with decreased insulin sensitivity and the development of type 2 diabetes in a community-based cohort of elderly men. Diabetes Care 2013, 36, 163–165. [Google Scholar] [CrossRef]
- Ren, X.; Wang, W.; Cao, H.; Shao, F. Diagnostic value of serum cathepsin S in type 2 diabetic kidney disease. Front. Endocrinol. 2023, 14, 1180338. [Google Scholar] [CrossRef]
- Reddy, G.R.; Kotlyarevska, K.; Ransom, R.F.; Menon, R.K. The podocyte and diabetes mellitus: Is the podocyte the key to the origins of diabetic nephropathy? Curr. Opin. Nephrol. Hypertens. 2008, 17, 32–36. [Google Scholar] [CrossRef]
- Garg, P. A Review of Podocyte Biology. Am. J. Nephrol. 2018, 47 (Suppl. S1), 3–13. [Google Scholar] [CrossRef]
Non-Diabetes μg/L, Median (95% CI) N | Diabetes μg/L, Median (95% CI) N | p-Value Mann–Whitney Non-Diabetes vs. Diabetes | Insulin, No μg/L, Median (95% CI) N | Insulin, Yes μg/L, Median (95% CI) N | p-Value Mann–Whitney Insulin No vs. Insulin Yes | |
---|---|---|---|---|---|---|
PIVUS, male | 0.145 (0.13–0.16) 324 | 0.173 (0.144–0.210) 62 | p = 0.019 | 0.150 (0.135–0.160) 373 | 0.195 (0.127–0.320) 14 | p = 0.13 |
PIVUS, female | 0.335 (0.305–0.410) 355 | 0.370 (0.264–0.653) 46 | Ns | 0.335 (0.300–0.398) 389 | 1.29 (0.288–1.64) 13 | p = 0.026 |
ULSAM, male | 0.140 (0.132–0.153) 466 | 0.273 (0.185–0.320) 44 | p < 0.0001 | 0.145 (0.135–0.160) 507 | 0.510 (0.210–0.705) 3 | p = 0.024 |
Biomarker in Urine | Non-DM Median (95% CI) | DM Median (95% CI) | p-Value (Mann–Whitney) | Correlation to U-HPLBII-P Non-DM | Correlation to U-HPLBII-P DM |
---|---|---|---|---|---|
NGAL, μg/L | 17.2 (15.7–18.3) N = 565 | 26.4 (14.0–34.1) N = 50 | 0.04 | Rs = 0.25 p < 0.0001 | Rs = 0.47 p = 0.002 |
KIM-1, ng/L | 792 (730–873) N = 562 | 1066 (727–1290) N = 50 | 0.01 | Rs = 0.19 p < 0.0001 | Rs = 0.35 p = 0.02 |
Albumin, mg/L | 7 (6–8) N = 636 | 15 (11.9–30) N = 60 | 0.0003 | Rs = 0.253 p < 0.0001 | Rs = 0.39 p = 0.01 |
Biomarker in serum | |||||
Cystatin C, mg/L | 1.03 (1.02–1.05) N = 702 | 1.12 (1.03–1.16) N = 69 | 0.02 | Rs = 0.03 Ns | Rs = −0.19 Ns |
Cathepsin S, ng/L | 265 (245–290) N = 456 | 512 (399–605) N = 46 | <0.0001 | Rs = 0.42 p < 0.0001 | Rs = 0.70 p < 0.0001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Xu, S.; Larsson, A.; Lind, L.; Lindskog, C.; Ärnlöv, J.; Venge, P. The Human Phospholipase B-II Precursor (HPLBII-P) in Urine as a Novel Biomarker of Increased Glomerular Production or Permeability in Diabetes Mellitus? J. Clin. Med. 2024, 13, 2629. https://doi.org/10.3390/jcm13092629
Xu S, Larsson A, Lind L, Lindskog C, Ärnlöv J, Venge P. The Human Phospholipase B-II Precursor (HPLBII-P) in Urine as a Novel Biomarker of Increased Glomerular Production or Permeability in Diabetes Mellitus? Journal of Clinical Medicine. 2024; 13(9):2629. https://doi.org/10.3390/jcm13092629
Chicago/Turabian StyleXu, Shengyuan, Anders Larsson, Lars Lind, Cecilia Lindskog, Johan Ärnlöv, and Per Venge. 2024. "The Human Phospholipase B-II Precursor (HPLBII-P) in Urine as a Novel Biomarker of Increased Glomerular Production or Permeability in Diabetes Mellitus?" Journal of Clinical Medicine 13, no. 9: 2629. https://doi.org/10.3390/jcm13092629